AGO-OVAR DESKTOP III (Protocol AGO - OVAR OP.4) - ppt video online download
Shannon Westin, MD, MPH, FASCO on X: "DESKTOP III demonstrated improved PFS and OS for patients that underwent surgery for recurrent #ovariancancer #ASCO20 #SGOatASCO #gyncsm https://t.co/z0dEmwPzOk" / X
Shannon Westin, MD, MPH, FASCO on X: "This #ASCO20 was notable for two major trials exploring secondary cytoreductive surgery in recurrent #ovariancancer - DESKTOP III and SOC -1 #ASCO20 #SGOatASCO #gyncsm https://t.co/pHGWklYWKs" /
Phil Beale highlights the results of DESKTOP3 - ANZGOG
Dr. STEFANY CARDOSO FARIA - MÉDICO ONCOLOGISTA: #ASCO 2017 Randomized controlled phase III study evaluating the impact of secondary cytoreductive surgery in recurrent ovarian cancer: AGO DESKTOP III/ENGOT ov20
Custom Presentation Assembly in Veeva CRM Desktop | Veeva
Dr. STEFANY CARDOSO FARIA - MÉDICO ONCOLOGISTA: #ASCO 2017 Randomized controlled phase III study evaluating the impact of secondary cytoreductive surgery in recurrent ovarian cancer: AGO DESKTOP III/ENGOT ov20
AGO DESKTOP III/ENGOT-ov20: Impact of secondary cytoreductive surgery in recurrent ovarian cancer - ecancer
Best of ASCO 2020
ASCO 2023 | Novartis
Shannon Westin, MD, MPH, FASCO on X: "This #ASCO20 was notable for two major trials exploring secondary cytoreductive surgery in recurrent #ovariancancer - DESKTOP III and SOC -1 #ASCO20 #SGOatASCO #gyncsm https://t.co/pHGWklYWKs" /
Phil Beale highlights the results of DESKTOP3 - ANZGOG
2020 ASCO Annual Meeting - Conference Program - Clin Onc 2020 - 22991 | CCO
Science Talk - ASCO 2023: Cancer experts gather in Chicago - The Institute of Cancer Research, London
Fumiko Ladd Chino, MD on X: "🚨@Oncoalert: Dr Helen MacKay summarizes #gyncsm highlights including Desktop III (compared to Soc-1 and GOG-213) for recurrent epithelial #ovariancancer showing a 7.7 month OS benefit from
LE GINECO A L'ASCO 2022 !
Frontiers | Prediction Models for Complete Resection in Secondary Cytoreductive Surgery of Patients With Recurrent Ovarian Cancer
ASCO 2020: AGO DESKTOP III Highlights Importance of Complete Resection in Recurrent Ovarian Cancer | PracticeUpdate
ASCO: Adding ribociclib to hormone therapy improves outcomes in patients with early breast cancer | UCLA Health
Is Secondary Cytoreduction in Recurrent Ovarian Cancer Necessary? - CancerConnect
GEMSTONE Educational Module Last Update: April 9, ppt download
Shannon Westin, MD, MPH, FASCO on X: "Patient selection clearly matters - DESKTOP III used the AGO criteria, SOC-1 used iMODEL score - both have been validated to predict ability to achieve
Ovarian Cancer: Standards of Care and New Opportunities - ppt video online download
Dr. STEFANY CARDOSO FARIA - MÉDICO ONCOLOGISTA: #ASCO 2017 Randomized controlled phase III study evaluating the impact of secondary cytoreductive surgery in recurrent ovarian cancer: AGO DESKTOP III/ENGOT ov20
AGO DESKTOP III/ENGOT-ov20: Impact of secondary cytoreductive surgery in recurrent ovarian cancer - ecancer
